Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Analysis of Plasma Tenascin-C in Post-HCV Cirrhosis: A Prospective Study.

Benbow JH, Elam AD, Bossi KL, Massengill DL, Brandon-Warner E, Anderson WE, Culberson CR, Russo MW, deLemos AS, Schrum LW.

Dig Dis Sci. 2018 Mar;63(3):653-664. doi: 10.1007/s10620-017-4860-z. Epub 2018 Jan 12.

PMID:
29330728
2.

Adeno-Associated Virus Serotype 2 Vector-Mediated Reintroduction of microRNA-19b Attenuates Hepatic Fibrosis.

Brandon-Warner E, Benbow JH, Swet JH, Feilen NA, Culberson CR, McKillop IH, deLemos AS, Russo MW, Schrum LW.

Hum Gene Ther. 2018 Jun;29(6):674-686. doi: 10.1089/hum.2017.035. Epub 2018 Mar 1.

3.

Viral hepatitis and hepatocellular carcinoma: etiology and management.

Zamor PJ, deLemos AS, Russo MW.

J Gastrointest Oncol. 2017 Apr;8(2):229-242. doi: 10.21037/jgo.2017.03.14. Review.

4.

Risk factors for hepatocellular carcinoma in cirrhosis due to nonalcoholic fatty liver disease: A multicenter, case-control study.

Corey KE, Gawrieh S, deLemos AS, Zheng H, Scanga AE, Haglund JW, Sanchez J, Danford CJ, Comerford M, Bossi K, Munir S, Chalasani N, Wattacheril J.

World J Hepatol. 2017 Mar 8;9(7):385-390. doi: 10.4254/wjh.v9.i7.385.

5.

Processing of miR17-92 Cluster in Hepatic Stellate Cells Promotes Hepatic Fibrogenesis During Alcohol-Induced Injury.

Brandon-Warner E, Feilen NA, Culberson CR, Field CO, deLemos AS, Russo MW, Schrum LW.

Alcohol Clin Exp Res. 2016 Jul;40(7):1430-42. doi: 10.1111/acer.13116. Epub 2016 Jun 13.

6.

Amoxicillin-Clavulanate-Induced Liver Injury.

deLemos AS, Ghabril M, Rockey DC, Gu J, Barnhart HX, Fontana RJ, Kleiner DE, Bonkovsky HL; Drug-Induced Liver Injury Network (DILIN).

Dig Dis Sci. 2016 Aug;61(8):2406-16. doi: 10.1007/s10620-016-4121-6. Epub 2016 Mar 22.

7.

Diet-Induced Obesity Enhances Progression of Hepatocellular Carcinoma through Tenascin-C/Toll-Like Receptor 4 Signaling.

Benbow JH, Thompson KJ, Cope HL, Brandon-Warner E, Culberson CR, Bossi KL, Li T, Russo MW, Gersin KS, McKillop IH, deLemos AS, Schrum LW.

Am J Pathol. 2016 Jan;186(1):145-58. doi: 10.1016/j.ajpath.2015.09.015. Epub 2015 Nov 18.

PMID:
26603137
8.

Genome-wide identification of microRNAs regulating cholesterol and triglyceride homeostasis.

Wagschal A, Najafi-Shoushtari SH, Wang L, Goedeke L, Sinha S, deLemos AS, Black JC, Ramírez CM, Li Y, Tewhey R, Hatoum I, Shah N, Lu Y, Kristo F, Psychogios N, Vrbanac V, Lu YC, Hla T, de Cabo R, Tsang JS, Schadt E, Sabeti PC, Kathiresan S, Cohen DE, Whetstine J, Chung RT, Fernández-Hernando C, Kaplan LM, Bernards A, Gerszten RE, Näär AM.

Nat Med. 2015 Nov;21(11):1290-7. doi: 10.1038/nm.3980. Epub 2015 Oct 26.

9.

Changing the face of hepatitis C management - the design and development of sofosbuvir.

Noell BC, Besur SV, deLemos AS.

Drug Des Devel Ther. 2015 Apr 24;9:2367-74. doi: 10.2147/DDDT.S65255. eCollection 2015. Review.

10.

Recurrent hepatitis C after liver transplant.

deLemos AS, Schmeltzer PA, Russo MW.

World J Gastroenterol. 2014 Aug 21;20(31):10668-81. doi: 10.3748/wjg.v20.i31.10668. Review.

11.

Drug-induced liver injury with autoimmune features.

deLemos AS, Foureau DM, Jacobs C, Ahrens W, Russo MW, Bonkovsky HL.

Semin Liver Dis. 2014 May;34(2):194-204. doi: 10.1055/s-0034-1375959. Epub 2014 May 31. Review.

PMID:
24879983
12.

Immunoglobulin g4-associated cholangitis: the next great masquerader.

Delemos AS, Pratt DS.

Gastroenterol Hepatol (N Y). 2013 Apr;9(4):255-6. Review. No abstract available.

13.

Hepatitis C treatment: an incipient therapeutic revolution.

deLemos AS, Chung RT.

Trends Mol Med. 2014 Jun;20(6):315-21. doi: 10.1016/j.molmed.2014.02.002. Epub 2014 Mar 11. Review.

PMID:
24636306
14.

Pharmacological inhibition of a microRNA family in nonhuman primates by a seed-targeting 8-mer antimiR.

Rottiers V, Obad S, Petri A, McGarrah R, Lindholm MW, Black JC, Sinha S, Goody RJ, Lawrence MS, deLemos AS, Hansen HF, Whittaker S, Henry S, Brookes R, Najafi-Shoushtari SH, Chung RT, Whetstine JR, Gerszten RE, Kauppinen S, Näär AM.

Sci Transl Med. 2013 Nov 20;5(212):212ra162. doi: 10.1126/scitranslmed.3006840.

15.

Expanding the donor pool in liver transplantation: Extended criteria donors.

deLemos AS, Vagefi PA.

Clin Liver Dis (Hoboken). 2013 Aug 19;2(4):156-159. doi: 10.1002/cld.222. eCollection 2013 Aug. Review. No abstract available.

16.

Systemic causes of cholestasis.

Delemos AS, Friedman LS.

Clin Liver Dis. 2013 May;17(2):301-17. doi: 10.1016/j.cld.2012.11.001. Epub 2013 Jan 26. Review.

17.

An intrinsic circadian clock of the pancreas is required for normal insulin release and glucose homeostasis in mice.

Sadacca LA, Lamia KA, deLemos AS, Blum B, Weitz CJ.

Diabetologia. 2011 Jan;54(1):120-4. doi: 10.1007/s00125-010-1920-8. Epub 2010 Oct 3.

18.

Parvin-beta inhibits breast cancer tumorigenicity and promotes CDK9-mediated peroxisome proliferator-activated receptor gamma 1 phosphorylation.

Johnstone CN, Mongroo PS, Rich AS, Schupp M, Bowser MJ, Delemos AS, Tobias JW, Liu Y, Hannigan GE, Rustgi AK.

Mol Cell Biol. 2008 Jan;28(2):687-704. Epub 2007 Nov 12.

19.

Identification of genetic variants in endothelial lipase in persons with elevated high-density lipoprotein cholesterol.

deLemos AS, Wolfe ML, Long CJ, Sivapackianathan R, Rader DJ.

Circulation. 2002 Sep 10;106(11):1321-6.

PMID:
12221047
20.

The frequency of the cholesteryl ester transfer protein-TaqI B2 allele is lower in African Americans than in Caucasians.

Cuchel M, Wolfe ML, deLemos AS, Rader DJ.

Atherosclerosis. 2002 Jul;163(1):169-74.

PMID:
12048136
21.

Electron beam computed tomography for the quantification of aortic valvular calcification.

Kizer JR, Gefter WB, deLemos AS, Scoll BJ, Wolfe ML, Mohler ER 3rd.

J Heart Valve Dis. 2001 May;10(3):361-6.

PMID:
11380099

Supplemental Content

Loading ...
Support Center